← Leaderboards
Louis D Falo
University Of Pittsburgh At Pittsburgh
$30,012,458
Attributed
$34,721,378
Total exposure
23
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$37,217,048 · 23
FDA$0 · 1
By mechanism
R01$19,628,991 · 11
U19$4,640,499 · 1
P50$4,552,584 · 5
U54$2,495,670 · 1
P01$1,925,870 · 3
RC1$1,716,083 · 1
Top collaborators
- Adriana T Larregina10 shared
- Fiona Ginty5 shared
- Arivarasan Karunamurthy5 shared
- Steven R Little5 shared
- Grace M. Aldrovandi1 shared
- Andrea Gambotto1 shared
- Charles R Rinaldo1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Roy A Mariuzza$20,943,458
- Steven R Little$5,142,670
- Meryl H Karol$246,914
Others in their field
Top investigators on “Skin”
- David Heimbrook · Leidos Biomedical Research, Inc.$121,104,269
- Donald Ym Leung · University Of Colorado Denver$58,473,424
- Thomas S. Kupper · Dana-Farber Cancer Institute$53,329,207
- Elaine Fuchs · University Of Chicago$41,573,105
- Timothy Burgess · National Institute Of Allergy And Infectious Diseases$35,600,000
- David Leung · National Jewish Health$31,859,607
Research focus
SkinAntigensCutaneousDesignClinical TrialsResponseImmunizationT-LymphocyteImmuneImmunityImmune ResponseMediatingEngineeringImmunotherapyIn VivoBaseDendritic CellsAntigen-Presenting CellsLaboratoriesCellsTechnologyPreventNovel StrategiesGenerations
Grant awards (85)
Multiscale, Multimodal Analysis of Skin and Spatial Cell Organization$749,994
U54 · FY2025 · AR
Engineering the Skin Immune System to Induce Systemic Immune Responses$642,652
R01 · FY2025 · AR · contact PI
Core C: Microneedle Patch Vaccines$4,640,499
U19 · FY2024 · AI · contact PI
Multiscale, Multimodal Analysis of Skin and Spatial Cell Organization$750,000
U54 · FY2024 · AR
Engineering the Skin Immune System to Induce Systemic Immune Responses$642,652
R01 · FY2024 · AR · contact PI
Project 3: Localized microneedle-directed combination immunotherapy for cSCC$381,600
P50 · FY2024 · CA · contact PI
Engineering the Skin Immune System to Induce Systemic Immune Responses$662,528
R01 · FY2023 · AR · contact PI
Engineering the Skin Microenvironment to Promote Allergen Tolerance$608,085
R01 · FY2023 · AR · contact PI
Multiscale, Multimodal Analysis of Skin and Spatial Cell Organization$477,802
U54 · FY2023 · AR
Project 3: Localized microneedle-directed combination immunotherapy for cSCC$369,675
P50 · FY2023 · CA · contact PI
Multiscale, Multimodal Analysis of Skin and Spatial Cell Organization$17,993
U54 · FY2023 · AR
Engineering the Skin Immune System to Induce Systemic Immune Responses$651,707
R01 · FY2022 · AR · contact PI
Engineering the Skin Microenvironment to Promote Allergen Tolerance$602,005
R01 · FY2022 · AR · contact PI
Multiscale, Multimodal Analysis of Skin and Spatial Cell Organization$499,881
U54 · FY2022 · AR
Project 3: Localized microneedle-directed combination immunotherapy for cSCC$378,023
P50 · FY2022 · CA · contact PI
Engineering the Skin Immune System to Induce Systemic Immune Responses$652,360
R01 · FY2021 · AR · contact PI
MNA Delivery of Neurokinin 1 Receptor Antagonists to Treat Atopic Dermatitis$472,668
R01 · FY2021 · AR · contact PI
Project 3: Localized microneedle-directed combination immunotherapy for cSCC$363,863
P50 · FY2021 · CA · contact PI
Clinical evaluation of SARS-CoV-2 subunit vaccine in a Phase I human clinical study$1,225,641
UM1 · FY2020 · AI
Engineering the Skin Microenvironment to Promote Allergen Tolerance$608,085
R01 · FY2020 · AR · contact PI
MNA Delivery of Neurokinin 1 Receptor Antagonists to Treat Atopic Dermatitis$487,287
R01 · FY2020 · AR · contact PI
Engineering the Skin Microenvironment to Promote Allergen Tolerance$608,085
R01 · FY2019 · AR · contact PI
MNA Delivery of Neurokinin 1 Receptor Antagonists to Treat Atopic Dermatitis$487,287
R01 · FY2019 · AR · contact PI
Manipulating Cutaneous Neuroimmunity to Treat Contact Dermatitis$370,510
R01 · FY2019 · AR · contact PI
Engineering the Skin Microenvironment to Promote Allergen Tolerance$608,085
R01 · FY2018 · AR · contact PI
MNA Delivery of Neurokinin 1 Receptor Antagonists to Treat Atopic Dermatitis$487,287
R01 · FY2018 · AR · contact PI
Manipulating Cutaneous Neuroimmunity to Treat Contact Dermatitis$394,132
R01 · FY2018 · AR · contact PI
An In Situ Patient-specific Chemo-Immunotherapy for Skin Cancers$66,832
P50 · FY2018 · CA · contact PI
MNA Delivery of Neurokinin 1 Receptor Antagonists to Treat Atopic Dermatitis$487,287
R01 · FY2017 · AR · contact PI
An In Situ Patient-specific Chemo-Immunotherapy for Skin Cancers$425,907
P50 · FY2017 · CA · contact PI
Manipulating Cutaneous Neuroimmunity to Treat Contact Dermatitis$420,971
R01 · FY2017 · AR · contact PI
Manipulating Cutaneous Neuroimmunity to Treat Contact Dermatitis$451,473
R01 · FY2016 · AR · contact PI
An In Situ Patient-specific Chemo-Immunotherapy for Skin Cancers$395,401
P50 · FY2016 · CA · contact PI
Manipulating Cutaneous Neuroimmunity to Treat Contact Dermatitis$486,132
R01 · FY2015 · AR · contact PI
An In Situ Patient-specific Chemo-Immunotherapy for Skin Cancers$398,375
P50 · FY2015 · CA · contact PI
An In Situ Patient-specific Chemo-Immunotherapy for Skin Cancers$444,330
P50 · FY2014 · CA · contact PI
An In Situ Patient-specific Chemo-Immunotherapy for Skin Cancers$388,443
P50 · FY2013 · CA · contact PI
Fabrication and Characterization of Dissolvable Microneedle Arrays for Effective$372,978
R01 · FY2013 · EB · contact PI
Fabrication and Characterization of Dissolvable Microneedle Arrays for Effective$409,896
R01 · FY2012 · EB · contact PI
Immunization Strategies for Autologous HIV Immunotherapy$371,213
R01 · FY2012 · AI · contact PI
Augmentation of Dendritic Cell-based Immunotherapy for Sezary Syndrome by T-reg D$220,652
P50 · FY2012 · CA · contact PI
Fabrication and Characterization of Dissolvable Microneedle Arrays for Effective$421,686
R01 · FY2011 · EB · contact PI
Immunization Strategies for Autologous HIV Immunotherapy$371,213
R01 · FY2011 · AI · contact PI
Augmentation of Dendritic Cell-based Immunotherapy for Sezary Syndrome by T-reg D$192,082
P50 · FY2011 · CA · contact PI
Novel Cutaneous Radiation Injury Countermeasures$716,083
RC1 · FY2010 · AI · contact PI
Fabrication and Characterization of Dissolvable Microneedle Arrays for Effective$447,629
R01 · FY2010 · EB · contact PI
Immunization Strategies for Autologous HIV Immunotherapy$374,963
R01 · FY2010 · AI · contact PI
Immunization Strategies for Autologous HIV Immunotherapy$245,890
R01 · FY2010 · AI · contact PI
Augmentation of Dendritic Cell-based Immunotherapy for Sezary Syndrome by T-reg D$201,457
P50 · FY2010 · CA · contact PI
Immunization Strategies for Autologous HIV Immunotherapy$378,750
R01 · FY2009 · AI · contact PI
Dendritic Cell Threapy for Cutaneous T-Cell Lymphoma$288,651
R01 · FY2009 · CA · contact PI
Augmentation of Dendritic Cell-based Immunotherapy for Sezary Syndrome by T-reg D$201,152
P50 · FY2009 · CA · contact PI
Novel Cutaneous Radiation Injury Countermeasures$1,000,000
RC1 · FY2008 · AI · contact PI
Dendritic Cell Vaccines to Elicit Polyspecific ThI type Anti- Tumor Immunity$392,647
P01 · FY2008 · CA · contact PI
Immunization Strategies for Autologous HIV Immunotherapy$376,251
R01 · FY2008 · AI · contact PI
Mechanisms of cutaneous immunobiology:Skin immune organ$310,793
R01 · FY2008 · AI · contact PI
Dendritic Cell Threapy for Cutaneous T-Cell Lymphoma$288,651
R01 · FY2008 · CA · contact PI
Augmentation of Dendritic Cell-based Immunotherapy for Sezary Syndrome by T-reg D$124,792
P50 · FY2008 · CA · contact PI
Dendritic Cell Vaccines to Elicit Polyspecific ThI type Anti- Tumor Immunity$395,038
P01 · FY2007 · CA · contact PI
Mechanisms of cutaneous immunobiology:Skin immune organ$316,811
R01 · FY2007 · AI · contact PI
Dendritic Cell Threapy for Cutaneous T-Cell Lymphoma$288,651
R01 · FY2007 · CA · contact PI
Mechanisms of cutaneous immunobiology:Skin immune organ$326,274
R01 · FY2006 · AI · contact PI
Dendritic Cell Threapy for Cutaneous T-Cell Lymphoma$297,272
R01 · FY2006 · CA · contact PI
Development of Immunotherapeutics for Biodefense$289,542
U01 · FY2006 · AI · contact PI
DC VACCINE TO ELICIT POLYSPECIFIC THI ANTI-TUMOR IMMUNIT$248,486
P01 · FY2006 · CA · contact PI
Mechanisms of cutaneous immunobiology:Skin immune organ$334,125
R01 · FY2005 · AI
Dendritic Cell Therapy for Cutaneous T-Cell Lymphoma$304,425
R01 · FY2005 · CA
Development of Immunotherapeutics for Biodefense$296,524
U01 · FY2005 · AI
DC VACCINE TO ELICIT POLYSPECIFIC THI ANTI-TUMOR IMMUNIT$242,679
P01 · FY2005 · CA
HIV Therapeutics: Immunization Targeting Human Skin$236,486
R01 · FY2005 · AR
DC TUMOR CONJUGATE VACCINE FOR IMMUNOTHERAPY$0
R01 · FY2005 · FD
Mechanisms of cutaneous immunobiology:Skin immune organ$334,500
R01 · FY2004 · AI
Development of Immunotherapeutics for Biodefense$296,870
U01 · FY2004 · AI
HIV Therapeutics: Immunization Targeting Human Skin$236,486
R01 · FY2004 · AR
DC VACCINE TO ELICIT POLYSPECIFIC THI ANTI-TUMOR IMMUNIT$235,979
P01 · FY2004 · CA
HIV Therapeutics: Immunization Targeting Human Skin$237,283
R01 · FY2003 · AR
Development of Immunotherapeutics for Biodefense$148,774
U01 · FY2003 · AI
DNA BASED ADJUVANT IMMUNIZATION FOR HIV$392,879
R01 · FY2002 · AI
MECHANISMS OF DENDRITIC CELL BASED TUMOR IMMUNIZATION$0
P01 · FY2002 · CA
DNA BASED ADJUVANT IMMUNIZATION FOR HIV$546,600
R01 · FY2001 · AI
ADJUVANT HIV IMMUNOTHERAPY--DNA BASED IMMUNIZATION MODEL$0
P01 · FY2001 · AI
MECHANISMS OF DENDRITIC CELL BASED TUMOR IMMUNIZATION$0
P01 · FY2001 · CA
DNA BASED ADJUVANT IMMUNIZATION FOR HIV$287,357
R01 · FY2000 · AI
ADJUVANT HIV IMMUNOTHERAPY--DNA BASED IMMUNIZATION MODEL$213,937
P01 · FY2000 · AI
MECHANISMS OF DENDRITIC CELL BASED TUMOR IMMUNIZATION$197,104
P01 · FY2000 · CA